Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
News
On this page find all the latest news, events and activities that involves Dr. Falk Pharma.
Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
Following the footsteps of our founder
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
Dosing of the First United States Patient
...and expansion of the Phase 2b Study of Naronapride in Gastroparesis
Corum – Place To Share
Read about yesterday's groundbreaking ceremony for the building in which we will be working in as of 2026.
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-nonresponsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
ROSCREA, Ireland, and FREIBURG, Germany (GLOBE NEWSWIRE) [February, 7, 2024]– Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical…
First patient treated in phase iib study of Naronapride in patients with gastroparesis
Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both…
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of…
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
SAN DIEGO, January 3, 2022 – Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology
company pioneering a precision medicine…
Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma GmbH and Zedira announce start of the phase 2b clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue…
Renexxion Ireland Ltd. & Dr. Falk Pharma GmbH announce a Licensing and Collaboration Agreement
Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal…
TGA regulatory approval for Jorveza 0.5mg orally disintegrating tablets
Dr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza® 0.5mg orally disintegrating budesonide tablet -…
Adults with EOE market research survey
Dr. Falk Pharma would like to thank all responders to our survey on Adults with EoE.
Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant
Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant has been awarded to
Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody
SAN DIEGO and FREIBURG, Germany, Aug. 13, 2020 /PRNewswire/ — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to…